Abstract
The advanced development of synthetic lethality has opened the doors for specific anti-cancer medications of personalized medicine and efficient therapies against cancers. One of the most popular approaches being investigated is targeting DNA repair pathways as the implementation of the PARP inhibitor (PARPi) into individual or combinational therapeutic schemes. Such treatment has been effectively employed against homologous recombination-defective solid tumors as well as hematopoietic malignancies. However, the resistance to PARPi has been observed in both preclinical research and clinical treatment. Therefore, elucidating the mechanisms responsible for the resistance to PARPi is pivotal for the further success of this intervention. Apart from mechanisms of acquired resistance, the bone marrow microenvironment provides a pre-existing mechanism to induce the inefficiency of PARPi in leukemic cells. Here, we describe the pre-existing and acquired mechanisms of the resistance to PARPi-induced synthetic lethality. We also discuss the potential rationales for developing effective therapies to prevent/repress the PARPi resistance in cancer cells.
Reference159 articles.
1. The concept of synthetic lethality in the context of anticancer therapy;Nat. Rev. Cancer,2005
2. Hallmarks of cancer: The next generation;Cell,2011
3. DNA double-strand break repair by homologous recombination;Mutat. Res.,2004
4. Yang, H., Zhong, Y., Peng, C., Chen, J.Q., and Tian, D. (2010). Important role of indels in somatic mutations of human cancer genes. BMC Med. Genet., 11.
5. DNA double-strand break repair;Curr. Biol. CB,1999
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献